Disease relevance of Lomexin

• This antibacterial activity may give fenticonazole a useful role in the topical treatment of vaginal discharge and in mycotic skin infections that are superinfected with bacteria [1].
• Comparison of the in vitro activities of fenticonazole, other imidazoles, metronidazole, and tetracycline against organisms associated with bacterial vaginosis and skin infections [1].
• Single dose therapy of vaginal candidiasis: a comparative trial of fenticonazole vaginal ovules versus clotrimazole vaginal tablets [2].
• The success attained by fenticonazole treatment indicates that it is a first choice drug in the therapy of superficial dermatomycoses [3].
• The efficacy of fenticonazole 2% lotion was studied in patients suffering from pityriasis versicolor in a double-blind comparison with bifonazole 1% lotion, both applied once daily for three weeks [4].

High impact information on Lomexin

• Recurrent tinea pedis: a double blind study on the prophylactic use of fenticonazole powder [5].
• A double blind, randomized clinical trial was performed on twelve healthy volunteers to evaluate the irritation potential of fenticonazole 2% cream (Lomexin) and spray versus micomazole 2% cream and econazole 1% spray [6].
• There was no evidence of irritation after the treatments with fenticonazole cream, its excipients, miconazole cream and fenticonazole spray excipients, whereas signs of irritation were observed in four cases after treatment with the spray formulations (two after fenticonazole, two after econazole) [6].
• It is suggested that fenticonazole and cyclopyroxolamine are equally effective in eradicating cutaneous mycoses and that their efficacy and tolerance are comparable [7].
• A study has been conducted about ultrastructural changes induced by an imidazole derivative, fenticonazole (Lomexin), on Candida albicans blastoconidia [8].

Chemical compound and disease context of Lomexin

• The antifungal activity of alpha-(2,4-dichlorophenyl)-beta,N-imidazolylethyl 4-phenylthiobenzyl ether nitrate (fenticonazole, Rec 15/1476) in experimental dermatomycosis and candidiasis in guinea pigs was studied [9].
• Treatment of dermatomycoses with topical fenticonazole and econazole [10].
• The Salmonella mutagenicity assay on fenticonazole, a new antifungal imidazole derivative [11].
• On the basis of a randomized scheme, 40 patients affected by pityriasis versicolor, candidiasis or dermatophytosis were treated with fenticonazole 2% cream or with miconazole 2% cream [12].

Biological context of Lomexin

• The forward mutational assay on Schizosaccharomyces pombe and the mitotic gene conversion assay on Saccharomyces cerevisiae were performed in order to verify whether alpha-(2,4-dichlorophenyl)-beta,N-imidazolylethyl 4-phenylthiobenzyl ether nitrate (fenticonazole, Rec 15/1476) shows a potential mutagenicity [13].

Anatomical context of Lomexin

• When instilled into the conjunctival sac in rabbits fenticonazole led to a slight reddening of the mucosa in only one animal [14].

Associations of Lomexin with other chemical compounds

• The activity of alpha-(2,4-dichlorophenyl)-beta,N-imidazolylethyl 4-phenylthiobenzyl ether nitrate (fenticonazole, Rec 15/1476) compared with those of reference drugs, was tested in vitro on various bacteria and fungi [15].
• Various tests were used in order to ascertain any irritating, sensitising or toxic potential of alpha-(2,4-dichlorophenyl)-beta,N-imidazolylethyl 4-phenylthiobenzyl ether nitrate (fenticonazole, Rec 15/1476) when applied to the skin or to mucous membranes in gel or cream formulation [14].

Analytical, diagnostic and therapeutic context of Lomexin

• The development and validation of a high performance liquid chromatography (HPLC)/tandem mass spectrometry assay for fenticonazole in human plasma and comparison with an HPLC-UV method [16].
• Chiral discrimination by HPLC and CE and antifungal activity of racemic fenticonazole and its enantiomers [17].
• The investigation on the chirality of fenticonazole is reported in this study. rac-Fenticonazole was resolved by HPLC and by capillary electrophoresis (CE) [17].
• After treatment lasting 21.9 +/- 6.7 or 22.5 +/- 6.2 days, respectively, patients receiving fenticonazole or cyclopyroxolamine had negative microscopic findings and cultures were sterile [7].
• Fenticonazole vaginal ovules of 200 mg, 600 mg and 1,000 mg were administered to 42 women prior to gynecological surgery [18].

References